Hohimer Wealth Management LLC Grows Stake in AstraZeneca PLC (NASDAQ:AZN)

Hohimer Wealth Management LLC raised its stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 54.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,569 shares of the company's stock after acquiring an additional 6,938 shares during the quarter. Hohimer Wealth Management LLC's holdings in AstraZeneca were worth $1,438,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Sigma Planning Corp boosted its stake in AstraZeneca by 10.1% in the first quarter. Sigma Planning Corp now owns 4,529 shares of the company's stock valued at $333,000 after acquiring an additional 417 shares during the last quarter. Signaturefd LLC lifted its stake in shares of AstraZeneca by 5.7% during the 1st quarter. Signaturefd LLC now owns 63,563 shares of the company's stock valued at $4,672,000 after buying an additional 3,417 shares in the last quarter. Turtle Creek Wealth Advisors LLC purchased a new stake in shares of AstraZeneca during the 1st quarter valued at approximately $3,218,000. Bleakley Financial Group LLC lifted its stake in shares of AstraZeneca by 14.8% during the 1st quarter. Bleakley Financial Group LLC now owns 69,761 shares of the company's stock valued at $5,127,000 after buying an additional 8,986 shares in the last quarter. Finally, MQS Management LLC purchased a new stake in shares of AstraZeneca during the 1st quarter valued at approximately $422,000. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Stock Performance

NASDAQ AZN opened at $71.13 on Monday. AstraZeneca PLC has a 1 year low of $61.24 and a 1 year high of $87.68. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.90 and a quick ratio of 0.70. The stock has a market capitalization of $220.60 billion, a PE ratio of 28.57, a P/E/G ratio of 1.31 and a beta of 0.37. The company's 50 day simple moving average is $70.72 and its two-hundred day simple moving average is $70.84.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.14. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The business had revenue of $13.59 billion for the quarter, compared to analysts' expectations of $13.71 billion. During the same period in the prior year, the company posted $2.06 EPS. The business's revenue for the quarter was up 7.2% compared to the same quarter last year. Analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Berenberg Bank set a $97.00 price target on shares of AstraZeneca in a research note on Wednesday. BNP Paribas assumed coverage on shares of AstraZeneca in a research note on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price target on the stock. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $89.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.